SoftBank wants to push Neumann out of the CEO role ahead of the IPO.Technologyread more
The RNC paid $166,390 in August to the office of Mintz Levin for "legal and compliance services," according to a disclosure filing.Politicsread more
Trump has called Chairman Jerome Powell "clueless" and Fed officials "boneheads."The Fedread more
Trump's call with the foreign leader is reportedly the subject of a whistleblower's complaint that has spurred new accusations of wrongdoing from Democrats.Politicsread more
The solider, Jarrett William Smith, 24, of Fort Riley, Kansas, was charged with one count of distributing information related to explosives and weapons of mass destruction,...Politicsread more
Harvard economist N. Gregory Mankiw says ultra-wealthy couples could split their fortunes in half through divorce and avoid paying a wealth tax proposed by presidential...Wealthread more
The stock of opioid maker Mallinckrodt hit an all-time low Thursday following a report that the troubled pharmaceutical company hired restructuring advisors and is mulling bankruptcy.
Mallinckrodt CEO Mark Trudeau told investors at a conference that the "rumors and speculation are unfortunate." The company's shares, which plunged 39%, closing at $1.59, have lost 95% of their value in the past year and are even further from their 2015 peak of $132.51 a share.
Bloomberg on Wednesday reported that Mallinckrodt, which agreed Wednesday to pay $15.4 million to settle a drug bribery probe into a company it acquired in 2014, hired law firm Latham & Watkins and turnaround firm AlixPartners, citing unnamed sources. The drugmaker is facing mounting litigation tied to the U.S. opioid crisis.
"While we can't really comment specifically on any specific rumors, what we can say is like any company hires advisers for all different kinds of things all the time," Trudeau said at Wells Fargo's annual health-care conference in Boston on Thursday. "Unfortunately, people are putting a whole variety of things together and making assumptions of things completely independent of what we're trying to do as a company."
Trudeau said Mallinckrodt remains focused on trying to transform the company into one that's concentrated on drug development. Aside from opioids, Mallinckrodt is best known for selling another controversial drug. H.P. Acthar Gel, a 67-year-old drug, has $1 billion a year in sales.
A federal database made public earlier this year revealed Mallinckrodt to be the largest manufacturer of opioid painkillers between 2006 and 2012. About 2,000 lawsuits against opioid manufacturers and distributors have been consolidated in Ohio. The trial for the consolidated lawsuits is slated to begin next month.
"Obviously us and other companies are embroiled in a set of uncertainties that have never been seen," Trudeau said. "People are serving uncertainty with the actions we're taking, leading to some of the speculation we're seeing. It is unfortunate and does detract from what we're trying to get done."
Correction: H.P. Acthar Gel has $1 billion a year in sales. An earlier version mischaracterized the figure.